A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Rifamycin SV MMX for the Treatment of Traveler's Diarrhea.

Trial Profile

A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Rifamycin SV MMX for the Treatment of Traveler's Diarrhea.

Completed
Phase of Trial: Phase III

Latest Information Update: 23 Nov 2015

At a glance

  • Drugs Rifamycin (Primary)
  • Indications Traveller's diarrhoea
  • Focus Registrational; Therapeutic Use
  • Sponsors Salix Pharmaceuticals; Santarus
  • Most Recent Events

    • 04 Oct 2013 Results will be presented at IDWeek 2013 according to a Santarus media release. Results were also summarised in the media release.
    • 11 Sep 2012 Primary endpoint 'Time-to-clinical-cure' (Time to last unformed stool) has been met according to a Santarus media release.
    • 04 Sep 2012 Status changed from recruiting to completed according to ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top